{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:11:47Z","timestamp":1792843907703,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin<jats:sup>\u00ae<\/jats:sup>) is a non-replicating adenoviral vector-based gene therapy developed by Ferring Pharmaceuticals for the treatment of high-risk Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Nadofaragene firadenovec constitutes vector DNA that encodes for interferon (IFN)-\u03b12b and is the first approved gene therapy in bladder cancer. The production of IFN-\u03b12b by transfected urothelial cells is associated with anticancer activity, including immunostimulatory, antiangiogenic and apoptotic effects. In December 2022, nadofaragene firadenovec received its first global approval in the USA for the treatment of high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumours in adults. This article summarizes the milestones in the development of nadofaragene firadenovec leading to this first approval for this indication.<\/jats:p>","DOI":"10.1007\/s40265-023-01846-z","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T09:03:03Z","timestamp":1677661383000},"page":"353-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Nadofaragene Firadenovec: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"1846_CR1","unstructured":"U.S. Food & Drug Administration. FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer [media release]. 16 Dec 2022. https:\/\/www.fda.gov\/."},{"issue":"1","key":"1846_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ucl.2019.09.011","volume":"47","author":"VM Narayan","year":"2020","unstructured":"Narayan VM, Dinney CPN. Intravesical gene therapy. Urol Clin North Am. 2020;47(1):93\u2013101.","journal-title":"Urol Clin North Am"},{"key":"1846_CR3","unstructured":"Ferring Pharmaceuticals. Ferring receives approval from U.S. FDA for Adstiladrin for high-risk, BCG-unresponsive non-muscle invasive bladder cancer [media release]. 16 Dec 2022. https:\/\/www.ferring.com\/."},{"key":"1846_CR4","unstructured":"US National Institutes of Health. ClinicalTrials.gov trial record (NCT03710876). 2021. https:\/\/clinicaltrials.gov\/. Accessed 7 Feb 2023."},{"key":"1846_CR5","unstructured":"Ferring Pharmaceuticals. ADSTILADRIN\u00ae (nadofaragene firadenovec-vncg) suspension, for intravesical use: US prescribing information. 2022. https:\/\/www.fda.gov\/. Accessed 27 Jan 2023."},{"key":"1846_CR6","unstructured":"Ferring Pharmaceuticals. Ferring signs global agreement to commercialise novel gene therapy for bladder cancer patients [media release]. 3 May 2018. http:\/\/www.ferring.com."},{"key":"1846_CR7","unstructured":"FKD Therapies Oy. FKD Therapies acquires gene therapy rights from Merck Co [media release]. 20 Sep 2012. http:\/\/www.blomberg.com."},{"key":"1846_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114112","volume":"182","author":"PG Holder","year":"2022","unstructured":"Holder PG, Lim SA, Huang CS, et al. Engineering interferons and interleukins for cancer immunotherapy. Adv Drug Del Rev. 2022;182: 114112.","journal-title":"Adv Drug Del Rev."},{"issue":"1","key":"1846_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","volume":"66","author":"RJ Connor","year":"2005","unstructured":"Connor RJ, Anderson JM, Machemer T, et al. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology. 2005;66(1):224\u20139.","journal-title":"Urology"},{"issue":"3","key":"1846_CR10","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","volume":"190","author":"CPN Dinney","year":"2013","unstructured":"Dinney CPN, Fisher MB, Navai N, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190(3):850\u20136.","journal-title":"J Urol"},{"issue":"12","key":"1846_CR11","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1245\/s10434-016-5300-6","volume":"23","author":"N Navai","year":"2016","unstructured":"Navai N, Benedict WF, Zhang G, et al. Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon \u03b12b formulated in Syn3 for failures of Bacillus Calmette-Guerin (BCG) therapy in nonmuscle invasive bladder cancer. Ann Surg Oncol. 2016;23(12):4110\u20134.","journal-title":"Ann Surg Oncol"},{"key":"1846_CR12","doi-asserted-by":"crossref","unstructured":"Narayan V, Boorjian S, Alemozaffer M, et al. Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) [abstract no. P0746]. Eur Urol. 2021;79(Suppl 1):S1028\u20139.","DOI":"10.1016\/S0302-2838(21)01122-2"},{"key":"1846_CR13","unstructured":"Mitra AP, Narayan VM, Boorjian SA, et al. Anti-adenoviral antibody levels predict nadofaragene firadenovec response in BCG-unresponsive NMIBC: results from a phase 3 trial [abstract no. PD09-02]. J Urol. 2021;206(3 Suppl):e119\u201320."},{"issue":"1","key":"1846_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107\u201317.","journal-title":"Lancet Oncol"},{"key":"1846_CR15","doi-asserted-by":"crossref","unstructured":"Schuckman AK, Lotan Y, Boorjian SA, et al. Efficacy of intravesical nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): longer-term follow-up from the phase III trial [abstract no. MP16-01]. J Urol. 2021;206(Suppl 3):E296.","DOI":"10.1097\/JU.0000000000002001.01"},{"key":"1846_CR16","doi-asserted-by":"crossref","unstructured":"Lotan Y, Schuckman AK, Boorjian SA, et al. Phase III trial of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive, non-muscle invasive bladder cancer: two year follow-up in the TA\/T1 cohort [abstract no. MP16-02]. 2021;206(Suppl 3):E296.","DOI":"10.1097\/JU.0000000000002001.02"},{"issue":"30","key":"1846_CR17","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","volume":"35","author":"ND Shore","year":"2017","unstructured":"Shore ND, Boorjian SA, Canter DJ, et al. Intravesical rAd\u2013IFN\u03b1\/Syn3 for patients with high-grade, Bacillus Calmette-Guerin\u2013refractory or relapsed non\u2013muscle-invasive bladder cancer: a phase II randomized study. J Clin Oncol. 2017;35(30):3410\u20136.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s40265-023-01902-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01846-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01846-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01846-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T06:07:32Z","timestamp":1685858852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01846-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1846"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01846-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-023-01902-8","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"1 March 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-023-01902-8","URL":"https:\/\/doi.org\/10.1007\/s40265-023-01902-8","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}